Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cellavita HD in Huntington's Disease
NCT02728115Phase 1Unknown
- Sponsor
- Azidus Laboratories Limited
- Start
- Oct 2017
- Primary completion
- Dec 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of NestaCell in Huntington disease (HD) (2 arms), sponsored by Azidus Laboratories Limited. Primary endpoint: Safety of Cellavita HD at 5 years. Status: unknown.
02
Drugs
NestaCell
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on NCT02728115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02728115.